Rapport TherapeuticsNASDAQ: RAPP

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$4.95 B
-24%vs. 3y high
89%vs. sector
-vs. 3y high
-vs. sector
-21%vs. 3y high
96%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Thu, 14 Nov 2024 21:20:00 GMT
$21.98+$0.13(+0.59%)

Dividend

No data over the past 3 years
$0.00-$17.54 M

Analysts recommendations

Institutional Ownership

RAPP Latest News

Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting
globenewswire.com14 November 2024 Sentiment: POSITIVE

Poster presentations on Phase 2a trial seizure biomarker, preclinical, and Phase 1 clinical data Poster presentations on Phase 2a trial seizure biomarker, preclinical, and Phase 1 clinical data

Rapport semestriel Pilier 3 - 30 juin 2024
globenewswire.com17 September 2024 Sentiment: NEUTRAL

Veuillez trouver ci-joint le rapport annuel Pilier 3 au 30 juin 2024 Attachment Rapport semestriel Pilier 3 - 30 juin 2024

Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences
globenewswire.com05 September 2024 Sentiment: POSITIVE

BOSTON and SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders, today announced presentations at two upcoming medical conferences: the International League Against Epilepsy (ILAE) 15th Annual European Epilepsy Congress (EEC) in Rome, Italy, September 7-11, 2024, and the 2024 Epilepsy Foundation Pipeline Conference in Atlanta, Ga., September 25-26, 2024.

What type of business is Rapport Therapeutics?

Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.

What sector is Rapport Therapeutics in?

Rapport Therapeutics is in the Healthcare sector

What industry is Rapport Therapeutics in?

Rapport Therapeutics is in the Biotechnology industry

What country is Rapport Therapeutics from?

Rapport Therapeutics is headquartered in United States

What is Rapport Therapeutics website?

https://www.rapportrx.com

Is Rapport Therapeutics in the S&P 500?

No, Rapport Therapeutics is not included in the S&P 500 index

Is Rapport Therapeutics in the NASDAQ 100?

No, Rapport Therapeutics is not included in the NASDAQ 100 index

Is Rapport Therapeutics in the Dow Jones?

No, Rapport Therapeutics is not included in the Dow Jones index

When was Rapport Therapeutics the previous earnings report?

No data

When does Rapport Therapeutics earnings report?

The next expected earnings date for Rapport Therapeutics is 28 February 2025